Compare CLMB & DMAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CLMB | DMAC |
|---|---|---|
| Founded | 1982 | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Retail: Computer Software & Peripheral Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 387.6M | 347.5M |
| IPO Year | 1996 | 2018 |
| Metric | CLMB | DMAC |
|---|---|---|
| Price | $20.74 | $5.81 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 4 |
| Target Price | ★ $80.00 | $15.50 |
| AVG Volume (30 Days) | ★ 186.8K | 139.1K |
| Earning Date | 04-29-2026 | 05-13-2026 |
| Dividend Yield | ★ 0.60% | N/A |
| EPS Growth | ★ 14.29 | N/A |
| EPS | ★ 0.18 | N/A |
| Revenue | ★ $652,517,000.00 | $500,000.00 |
| Revenue This Year | $7.82 | N/A |
| Revenue Next Year | $5.83 | N/A |
| P/E Ratio | $113.67 | ★ N/A |
| Revenue Growth | ★ 40.14 | N/A |
| 52 Week Low | $15.25 | $3.48 |
| 52 Week High | $145.00 | $10.42 |
| Indicator | CLMB | DMAC |
|---|---|---|
| Relative Strength Index (RSI) | 36.37 | 39.96 |
| Support Level | $18.97 | $5.76 |
| Resistance Level | $23.60 | $6.40 |
| Average True Range (ATR) | 1.07 | 0.37 |
| MACD | 1.24 | -0.04 |
| Stochastic Oscillator | 92.10 | 26.48 |
Climb Global Solutions Inc is a cloud-based, value-added IT distribution and solutions company specializing in emerging technologies. It operates across the USA, Canada, United Kingdom, and Europe through multiple business units, including Climb Channel Solutions, Sigma, Grey Matter, Interwork, and TechXtend. The company is organized into two reportable operating segments. The Distribution segment distributes technical software to corporate resellers, value-added resellers (VARs), consultants, and systems integrators under the name Climb Channel Solutions. The Solutions segment is a cloud solutions provider and value-added reseller of software, hardware, and services to customers under the name Grey Matter.
DiaMedica Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing treatment for ischemic diseases with two main clinical programs focused on acute ischemic stroke (AIS) and preeclampsia (PE). Its main product candidate DM199 (rinvecalinase alfa) is a recombinant form of human tissue kallikrein-1, which is a synthetic version of the naturally occurring protease enzyme kallikrein-1 and a rhKLK1 undergoing clinical development studies in both AIS and PE. The other product candidate in the company's pipeline is DM300, its patented recombinant human ulinastatin, a broad-spectrum serine protease inhibitor, being developed as a potential therapy for severe acute pancreatitis.